ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
9 announcements with these filters
SMS Pharmaceuticals released a press release on its Q2 and H1 FY27 results, showing strong growth. Management now expects FY27 revenue growth and EBITDA margins above earlier guidance.
Q2FY27 revenue ₹316 Cr (+30% YoY), EBITDA ₹68 Cr at 21% margin, PAT ₹40 Cr (+57%). Strategy: backward integration, high-value APIs, DMF/CEP filings, ₹280 Cr capex.
SMS Pharmaceuticals' Company Secretary Thirumalesh Tumma resigned effective November 4, 2026. Manohar Mollama has been appointed as the new Company Secretary effective November 5, 2026.
SMS Pharmaceuticals Ltd reported revenue from operations of ₹316.1 Cr (+30.4% YoY) and net profit of ₹39.9 Cr (+57.7% YoY) for Q2 FY27.
SMS Pharmaceuticals received an Income Tax appellate order under Section 250 dismissing its appeal for AY 2018-19. The company says there is no material impact and is reviewing next steps.
SMS Pharmaceuticals disclosed that the CIT(Appeals) dismissed its appeal against a ₹7.19 Crore income tax assessment for AY 2018-19. The company is reviewing the order and expects no material impact.
SMS Pharmaceuticals received an Income Tax appellate order allowing its appeal for AY 2023-24. The outstanding tax demand of Rs.45.63 Crore, including interest, stands vacated.
SMS Pharmaceuticals has signed a loan agreement lending up to Rs.50 Crore to its 99.99%-owned subsidiary SMS Peptides. The unsecured, arm's-length facility has nil outstanding as on date.
SMS Pharmaceuticals has scheduled a board meeting for November 4, 2026, to consider Q2 FY27 unaudited results. This is a routine advance intimation.